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Abstract 
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to 
become the most commonly used first-line therapy for the treatment of metastatic renal cell 
carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the 
patients are intrinsically resistant to sunitinib and the remaining 70% who respond initially 
will eventually become resistant in 6–15 months. While the molecular mechanisms of 
acquired resistance to sunitinib have been unravelling at a rapid rate, the mechanisms of 
intrinsic resistance remain elusive. Combination therapy, sunitinib rechallenge and 
sequential therapy have been investigated as means to overcome resistance to sunitinib. Of 
these, sequential therapy appears to be the most promising strategy. This mini review 
summarises our emerging understanding of the molecular mechanisms, and the strategies 
employed to overcome sunitinib resistance. 
 
Introduction 
 
The past decade has witnessed tremendous 
improvements in the understanding of the 
role of angiogenesis in renal cell carcinoma 
(RCC), leading to the development and 
implementation of many angiogenesis-
inhibitors, also known as targeted 
therapies, in clinical practice (1-7). These 
achievements largely stem from the 
elucidation of two inter-connected 
molecular pathways that regulate 
angiogenesis and proliferation in RCC, an 
inactivated von Hippel Lindau (VHL) gene 
and activated mammalian target of 
rapamycin (mTOR) (6-11). These pathways 
have been extensively reviewed (8-18). Of 
the many targeted therapies, sunitinib has 
carved its way to become the most 
frequently used first-line therapy for the 
treatment of metastatic RCC. However, the 
initial enthusiasm is hampered by the 
development of intrinsic and extrinsic 
resistance to therapy. In this mini review, a 
summary of the angiogenesis pathway in 
RCC, the emerging molecular mechanisms 
of sunitinib resistance, and the approaches 
to overcome resistance to sunitinib in RCC 
are discussed.    
 
The VHL-HIF axis in RCC 
 
The VHL gene is inactivated in 70-80% of 
sporadic clear cell RCC either through 
mutations, hyper-methylations or loss of 
heterozygosity (8-10). Subsequently, the 
production of its functional protein, pVHL, 
is either inhibited or decreased in these 
cases. The best studied function of pVHL is 
the degradation of the transcription factor 
hypoxia-inducible factor (HIF). As the 
microenvironment of solid tumors is often 
hypoxic, tumor cells undergo adaptive 
changes to facilitate their survival. One 
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such survival mechanism under hypoxic 
conditions is the up-regulation of HIF-
alpha (HIF-α). Under normoxic conditions, 
pVHL forms complexes with elongin B, 
elongin C, Rbx1 and cullin 2 to form a 
pVHL- E3 ubiquitin ligase complex (pVHL-
E3 complex) (15-23). The pVHL-E3 complex 
then binds to HIF-α, leading to its 
polyubiquitination and proteasomal 
degradation. In the absence of a functional 
pVHL, secondary to VHL mutations, the 
formation of the pVHL-E3 complex and its 
binding to HIF are inhibited and therefore, 
the degradation of HIF-α is prevented even 
in normoxic conditions (15-23). This leads 
to the stabilization and accumulation of 
HIF in cells (Figure 1). Subsequently, HIF is 
translocated to the nucleus, where it binds 
to hypoxia-responsive elements of the DNA 
and transactivates a plethora of molecules 
that regulate angiogenesis (Figure 1). The 
best studied of these molecules is the 
vascular endothelial growth factor (VEGF), 
a crucial regulator of vascular development 
during embryogenesis (vasculogenesis) and 
blood vessel formation from the existing 
endothelium in adults (angiogenesis) (24-
31).  
 
The role of VEGF in RCC 
 
In humans, the VEGF system consists of 
five secreted ligands, VEGF A-D and 
placenta growth factor-1 (PlGF), and three 
receptor tyrosine kinases, VEGF R1-R3. 
The binding of the ligands to the receptors 
initiates VEGF-mediated angiogenesis 
which involves endothelial cell 
proliferation, migration, permeability and 
capillary formation. However, VEGF alone 
is not sufficient for the maintenance and 
stabilization of the newly formed vessels, 
and requires input from the surrounding 
microenvironment. This support comes 
from surrounding peri-endothelial cells 
such as vascular smooth muscles (VSMC) 
and pericytes that stabilize the newly 
formed vasculature and support 
endothelial cell survival (32-34). This is 
achieved by the cross talk between platelet-
derived growth factor-B (PDGF-B) secreted 
by the endothelial cells and the receptor 
tyrosine kinases of PDGF, especially 
PDGFR-B, of the VSMC and pericytes (32-
35).  Thus the interplay between VEGF, 
PDGF and their tyrosine kinase receptors 
plays a crucial role in angiogenesis 
secondary to VHL inactivation in RCC. 
 
The role of mTOR in RCC 
 
mTOR, which exists as mTORC1 and 
mTORC2 complexes, is a key component of 
the phosphoinositide 3-kinase (PI3K)/Akt 
signalling pathway that regulate cell cycle, 
proliferation and angiogenesis (12, 36). 
mTOR signalling can be activated via a 
number of mechanisms, including 
overexpression of growth factor receptors, 
mutations in PI3K/Akt, tuberous sclerosis 
tumor suppressor genes TSC1/2 or 
phosphatase and tensin homolog (PTEN) 
(37-42). mTOR activates the translation of 
the pro-proliferative factors such as cyclin 
D1 and cMyc, and the angiogenic factor 
HIF through phosphorylation of ribosomal 
protein S6 kinase (S6K) and eukaryotic 
translation initiation factor 4E-binding 
protein 1 (4EBP1) (6, 43-45). The mTORC2, 
through protein kinase Cα, regulates cell 
morphology, motility, adhesion, invasion 
and metastasis (45). Furthermore, 
inactivation of VHL increases mTOR 
activity which in turn exacerbates the loss 
of VHL function leading to enhanced HIF 
activity (38) (Figure 1). VHL inactivation 
itself leads to deregulation of cyclin D1 (6, 
44). Thus mTOR activation is involved in 
cell proliferation through cyclin D1 and c-
Myc, and angiogenesis through HIF (Figure 
1).  
 
Targeted therapy in RCC 
 
Elucidation of these pathways had 
identified the potential of angiogenesis 
inhibition as a promising therapeutic 
option for metastatic RCC leading to the 
development and implementation of 
angiogenesis and mTOR inhibitors in 
clinical practice. These targeted therapies 
are broadly classified as VEGF inhibitors, 
multi-tyrosine kinase inhibitors and mTOR 
inhibitors. The most successful VEGF 
inhibitor is the humanized VEGF-
neutralizing antibody bevacizumab, which
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Figure 1.The role of VHL and mTOR in angiogenesis and proliferation of RCC. A non-functional 
VHL is the major risk factor for the development and progression of RCC. The functional protein of 
VHL, pVHL, complexes with E3-ligase and degrades HIF. When the VHL is non-functional, HIF is 
stabilized and translocated to nucleus where it binds with HIF responsive elements of the DNA and 
activates many pro-angiogenic factors including VEGF and PDGF. They interact with their respective 
tyrosine kinase receptors VEGFR (mostly at endothelial cells) and PDGFR (mostly at vascular smooth 
muscle cells and pericytes) and promote angiogenesis. The PI3K/AKT/mTOR pathway is activated by 
many factors including growth factor receptors. mTOR in turn activates cyclin D1 and cMyc and 
promotes cell proliferation and survival.  Furthermore, VHL inactivation also activates mTOR, which 
in turn up-regulates HIF and subsequent angiogenesis. GFR, growth factor receptor; HIF, hypoxia-
inducible factor; PDGF platelet-derived growth factor; PDGFR, receptor for PDGF; VEGF, vascular 
endothelial growth factor; VEGFR, receptor for VEGF; VHL,von Hippel Lindau gene. 
 
exerts its anti-angiogenic activity by acting 
against the angiogenic endothelial cells 
surrounding the tumor, rather than the 
tumor per se, thus blocking the supply of 
oxygen and nutrients to the tumors (46-
48). The multi-tyrosine kinase inhibitors 
are sunitinib, sorafenib, pazopanib and 
axitinib. Many more are in various phases 
of clinical trials. They inhibit multiple 
tyrosine kinase receptors and neutralize 
the downstream signalling pathways 
activated by ligand-receptor binding that 
leads to angiogenesis. Two of the most 
successful mTOR inhibitors are 
temsirolimus and everolimus. Both are 
rapamycin analogues and bind to FK506-
binding protein 12 (FKBP12), which in turn 
binds to mTOR leading to the inhibition of 
the PI3K/Akt/mTOR pathway (45, 49). In 
addition, temsirolimus has been shown to 
have a direct inhibitory effect on HIF and 
VEGF (50). Of these targeted therapeutics, 
sunitinib has become the most frequently 
used first-line targeted therapeutic for the 
treatment of metastatic RCC. 
 
Sunitinib in RCC 
 
Sunitinib malate (SUTENT®) is a small 
molecule multi-tyrosine kinase inhibitor 
that inhibits VEGFR-1, -2 and -3, PDGFR-α 
and -β, stem cell factor receptor (KIT), Fms-
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like tyrosine kinase 3, colony stimulating 
factor type 1 receptor and the glial cell-line-
derived neurotrophic factor receptor (RET) 
(51). Phase II trials of sunitinib in cytokine-
refractory RCC patients showed response 
rates of 39-40%, stable disease rates of 23-
27%, median time to tumor progression of 
8.7 months, and a median survival of 16.4 
months (52-55), leading to its accelerated 
approval for RCC in 2006. This was 
followed by regular approval in 2007 based 
on a phase III clinical trial that showed 
superior outcome as a first-line therapy 
when compared with interferon alpha in 
patients with clear cell RCC (1, 3, 51, 55). 
Subsequently, immunotherapy, which used 
to be the mainstay of treatment for 
metastatic RCC, was replaced by targeted 
therapy, and sunitinib has become the 
most commonly used first-line therapy for 
metastatic RCC. 
 
Intrinsic and acquired resistance to 
sunitinib 
 
Despite the benefits achieved through 
sunitinib in terms of progression-free 
survival and disease stabilization, all 
patients develop resistance to sunitinib and 
eventually relapse. While the criteria for 
defining resistance or response to therapy 
based on  RECIST (response evaluation 
criteria in solid tumors) are debatable as 
recently pointed out (56, 57), and 
investigators implement variations, based 
on the available data it is reasonable to 
conclude that approximately 70% of 
patients respond to therapy initially and 
the remaining 30% show primary 
resistance (intrinsic resistance) (57-59). In 
the 70% of patients who show initial 
response, durable responses are rare, and 
acquired resistance (extrinsic resistance) to 
treatment develops in almost all of them in 
6–15 months (56-63). 
 
The mechanisms of sunitinib resistance are 
varied and multifactorial. Table 1 
summarizes our emerging understanding of 
the molecular mechanisms of resistance to 
sunitinib. It should be noted that most of 
these mechanisms are based on pre-
clinical studies, and therefore, their 
relevance in clinical settings is yet to be 
verified. Taken together, the functional 
significance of these mechanisms can be 
summarized under two categories: 
restoration of angiogenesis through the 
activation of VEGF-independent pathways 
(64-69, 71-80) and reduced bioavailability 
either through increased efflux or 
lysosomal sequestration (70, 81). Of these, 
activation of tyrosine kinase-independent 
alternate angiogenesis pathways leading to 
restoration of angiogenesis appears to be 
gaining consensus.   
 
While the mechanisms of sunitinib-
mediated alternate angiogenesis are still 
elusive, hypoxia is emerging as the major 
culprit. Sunitinib inhibits angiogenesis, 
largely through the inhibition of VEGF and 
its receptors. This helps in the stabilization 
or regression of the tumor in the short 
term. However, this also results in hypoxia. 
Sustained hypoxia by sunitinib ‘resets’ the 
tumor microenvironment and leads to the 
development of a VEGF/VEGFR-
independent alternate angiogenic pathway 
through the up-regulation of angiogenic 
factors other than VEGF (60, 83). For 
example, as shown in Table 1, up-
regulation of IL-8 or down-regulation of 
IFN-γ (65, 69), may circumvent the anti-
angiogenic effects of sunitinib, and 
functionally compensate for the 
VEGF/VEGFR-mediated inhibition of 
angiogenesis. Apart from contributing to 
acquired resistance through alternate 
angiogenesis pathways, hypoxia could also 
contribute to intrinsic resistance by 
selecting a more malignant RCC 
phenotype, which may accelerate 
metastatic development and prone cells to 
insensitivity for anti-angiogenic treatment 
(59, 84). 
 
Overcoming resistance to sunitinib 
 
The pre-clinical studies (Table 1) have 
demonstrated the beneficial effects of 
adjunct therapy, targeted at the specific 
molecules identified at each study, to 
overcome resistance. However, their clinical 
relevance needs to be established. In 
patients, sunitinib rechallenge, 
combination therapy and sequential 
therapy have been investigated to overcome 
sunitinib resistance.  
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   Table 1. Emerging mechanisms of resistance to sunitinib 
Parameter Mechanism of Resistance Ref 
ATX* Endothelial ATX activates LPA signalling to promote 
renal tumorigenesis 
(64) 
Chemokines Down-regulation of angiostatic chemokines IFN-γ, 
IFN-γR and CXCL9 restores angiogenesis 
(65) 
COX-2 Enhanced COX-2 up-regulates HIF (66) 
EMMPRIN High EMMPRIN causes resistance via hyaluronan-
mediated activation of ErbB2 
(67) 
HDM2/HDMX Inhibition of p53 by HDM2 and HDMX restores 
angiogenesis 
(68) 
 
IL-8 
Increased plasma level leads to tumor growth and 
vascularity 
(69) 
Lysosomes Sequestration of sunitinib in lysosomes reduces 
bioavailability 
(70) 
MicroRNA Decreased miR-141promotes angiogenesis; 
increased miR-942, miR-628-5p, miR-133a, and 
miR-484 promote angiogenesis through up-
regulation of MMP-9 and VEGF 
(71, 72) 
MDSC Intra-tumoral MDSC provides sustained immune 
suppression and angiogenesis 
(73) 
NGAL Increased NGAL activates alternate pro-angiogenic 
signaling pathway such as Ras-GTP, Erk1/2, and 
STAT1α 
(74) 
Polymorphism CYP3A5 rs776746; VEGFR2 rs1870377; VEGFR3 
rs307826; VEGFR3 rs307821; 
VEGFR3 rs448012; PDGFRA rs1800812; IL-8 
rs4073; PXR rs3814055; ABCB1 rs2032582; ABCB1 
rs1128503 
(75-78) 
PRKX Overexpression up-regulates microphthalmia-
associated transcription factor (MITF) 
(79) 
PTEN  Inactivation of PTEN restores angiogenesis through 
activation of P13/Akt/mTOR 
(80) 
RLIP76 Active efflux of sunitinib from cells leads to reduced 
bioavailability 
(81) 
SKI SK1activates ERK and inhibits ATP-binding cassette 
(ABC) drug transporter family 
(82) 
*ATX, autotaxin; Cox-2, cycloxygenase-2; EMMPRIN, Extracellular matrix metalloproteinase inducer; 
HDM2, human double minute 2; HDMX, human double minute x; IL-8, interleukin-8; LPA, 
lysophosphatidic acid; MDSC, myeloid derived suppressor cells; NGAL, neutrophil gelatinase-
associated lipocalin; PRKX, protein kinase x-linked; PTEN, phosphatase and tensin homolog; RLIP76, 
ral-interacting protein 76; SKI,sphingosine kinase-1.  
 
The rationale for sunitinib rechallenge is 
that resistance to sunitinib is transient and 
that after a short treatment interruption, 
sensitivity to sunitinib can be restored by 
subsequent rechallenge. Evidence for this 
comes from a pre-clinical study, a 
retrospective study, and a case report. In 
the pre-clinical study, primary RCC cells 
isolated from patients who were resistant to 
sunitinib, when grown as a mouse 
xenograft, responded to sunitinib (85). In 
the retrospective study, of the 23 patients 
rechallenged with sunitinib, 5 patients 
(22%) achieved an objective partial 
response, and 17 patients (74%) had stable 
disease (86). The median progression-free 
survival (PFS) was 13.7 months with initial 
treatment, and 7.2 months with 
rechallenge. Patients who had an interval 
of more than 6 months between sunitinib 
rechallenge had a longer PFS than those 
who started the rechallenge within 6 
months (median PFS, 16.5 vs 6.0 months; 
P=.03). No substantial new toxicity or 
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significantly increased severity of prior 
toxicity was seen during rechallenge (86). A 
case report by Ravaud and colleagues 
showed that rechallenge with sunitinib 
resulted in a partial response for 12 
months in a 60-year old patient (61). 
Additional prospective studies are required 
to establish the beneficial effect of sunitinib 
rechallenge. 
 
Combination therapy aims to overcome the 
limitations of a single drug either by 
enhancing its effectiveness on a single 
pathway or acting on a different molecule 
thereby by blocking multiple pathways (60, 
87, 88). Medioni and colleagues (89) 
investigated a combination of sunitinib (25-
50 mg) with bevacizumab (10 mg/kg), as a 
salvage therapy after disease progression 
under sunitinib monotherapy. Of the 7 
patients, 2 patients showed a partial 
response, four had stable disease, and one 
patient had disease progression. The 
median PFS and overall survival were 8.5 
and 15.1 months respectively with a 
tolerable toxicity profile (89). Many phase I 
studies have investigated a combination of 
sunitinib with bevacizumab (90), interferon 
(91), temsirolimus (92), and everolimus (60, 
93). These studies were abandoned 
because of high degree of toxicities without 
any apparent benefits.  
 
The rationale for sequential therapy is that 
established resistance to sunitinib may be 
reversed with an alternate agent that either 
targets the same signalling pathway, or a 
different pathway (56, 59, 61, 94, 95). 
Sequential therapies that have been tested 
so far include axitinib (96), pazopanib (97, 
98), everolimus and temsirolimus (99). As 
recently summarized by Sun et al., the 
optimal sequential therapy appears to be 
sunitinib-axitinib-everolimus (100). The 
most promising finding is a recent case 
report by Raja, which employed six lines of 
sequential therapy in a 45-year old male 
patient: Sunitinib-everolimus-sorafenib-
bevacizumab/vinblastine/mitomycinC-
temsirolimus-bevacizumab/everolimus. 
This resulted in a survival of 49 months 
(101). 
 
Conclusion 
 
Intrinsic and extrinsic resistance to 
sunitinib remains a challenge in the 
effective treatment of metastatic RCC. The 
mechanisms of intrinsic resistance remain 
elusive, and much research is warranted in 
this largely unexplored area. At the same 
time, pre-clinical studies have been 
unravelling the molecular mechanisms of 
extrinsic or acquired resistance at a rapid 
rate. However, there is a wide gap between 
the bench and the bedside. While optimism 
remains that this gap will narrow in the 
years to come, at present, the best strategy 
to overcome resistance to sunitinib appears 
to be sequential therapy. There is no 
universal consensus as to the optimal 
sequence of therapy. While establishing a 
universal consensus for sequential therapy 
appears logical, the practicality of 
implementing such approach would be 
difficult, at least in part, due the 
heterogeneity of RCC. Thus personalised 
medicine could be one way to overcome 
resistance. To achieve this, discovery of a 
sunitinib resistance ‘biomarker map’ would 
be of utmost value. A close interaction 
between clinicians and basic scientists 
aimed at designing clinically relevant 
experiments will enable a speedy resolution 
to overcome sunitinib resistance in the 
days to come. 
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